The Gene and Virus Therapy Program (GVT) is currently comprised of 22 accomplished members, both basic scientists and clinician investigators from 10 departments and divisions working interactively to create novel gene transfer, virotherapy and immunovirotherapy approaches for the treatment of cancer. This goal is supported by 4 specific aims: 1) To develop novel gene and virus platforms for use in cancer therapy; 2) To develop cancer immunotherapies by exploring the immunomodulatory potential of gene- and virus-based therapeutics; 3) To assess preclinical, clinical, pharmacologic, and immunologic properties of vectors used in cancer therapy and optimize clinical application, and 4) To evaluate the role of cells as carriers in gene and virus therapy approaches to cancer therapy. In addition to intensive intraprogrammatic interactions, substantive interprogrammatic interactions, essential for the process of clinical translation, have been established between the GVT and other Mayo Clinic Cancer Center (MCCC) Programs including the Hematologic Malignancies Program (HMP), the Women's Cancer Program (WCP), the Gastrointestinal Cancer Program (GI), the Neuro- Oncology Program (NONC) and the Cancer Immunology and Immunotherapy Program (CII). The Leader, Dr. Evanthia Galanis, is an oncologist with considerable stature in the field of gene and virus therapy. Productivity of the Program during the current funding period has been significant, including direct funding of $8.9M (vs $7.2M at the 2013 renewal) and a total of 426 publications (as of 12/31/2017). In addition,multiple Phase I/II clinical trials of recombinant viruses or oncolytic virus infected carrier stem cells which were designed, constructed, preclinically tested, and manufactured at the Mayo Clinic have been launched and/or completed under several program sponsored IND. The efficacy observed with some of these approaches has led to later stage, randomized phase II trials. Additionally, there are several promising projects in the translational pipeline, including immunovirotherapy strategies employing virus strains encoding immunostimulatory transgenes such as MV-NAP in breast cancer, vesicular stomatitis virus libraries in melanoma and combinational strategies with immune checkpoint inhibitors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459

Showing the most recent 10 out of 1129 publications